GET DAILY SIGNALSZymeworks (ZYME) Set for Dramatic Q3 2026 Earnings Inflection
Key Takeaways
- Zymeworks reports its third-quarter 2026 results after the market close on November 9, 2026, and does not plan to host a conference call.
- Wall Street expects a sharp swing to profitability, with consensus EPS (earnings per share) near $2.29 to $2.40 versus a loss of $0.26 a year ago.
- Revenue is projected to surge to roughly $212 million to $250 million, up from $27.61 million in the prior-year quarter, driven largely by anticipated milestone payments.
- Full-year 2026 guidance of $278 million to $292 million in revenue means the third quarter is expected to carry most of the company's annual results.
- Recent quarters have been quiet: second-quarter 2026 revenue fell 90.6% year over year to $4.59 million, alongside a $0.62 per-share loss.
- For more context on the ticker, explore Major News, Today's Price Move, Price Targets, and Forecast.
- Discover automated ideas with Trending AI Robots to see how AI-driven strategies are scanning the market.
Why This Report Carries Extra Weight
ZYME is a clinical-stage biotechnology company developing multifunctional biotherapeutics for cancer and other diseases, while also managing a portfolio of licensed healthcare assets. Its third-quarter 2026 report carries outsized weight because the company's annual revenue guidance is heavily concentrated in this single period. After two consecutive quarters of minimal revenue, investors are watching whether anticipated milestone payments from collaboration partners actually materialize at the scale modeled by analysts. The result will test the credibility of management's full-year targets and the sustainability of a business model built around milestone and royalty income rather than recurring product sales. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Projected Earnings and Revenue Figures
Consensus estimates point to a dramatic one-quarter inflection. Zacks projects earnings of $2.40 per share on $249.68 million in revenue, while Yahoo Finance consensus sits near $2.29 per share on $212.43 million in revenue. Either figure represents a staggering turnaround from the $0.26 per-share loss and $27.61 million in revenue reported in the third quarter of 2025. The surge is expected to come from milestone payments tied to partnered programs rather than commercial product revenue. For full-year 2026, management has guided to $278 million to $292 million in revenue and $114 million to $128 million in adjusted EBITDA, figures that leave the third quarter shouldering most of the year's results.
Sentiment and Risks Heading Into the Print
Sentiment heading into this report is cautious despite the optimistic headline estimates. Because the expected revenue jump depends on lumpy, one-time milestone payments, analysts and investors are discounting the "beat" potential of the quarter. The company's two most recent prints missed expectations, with second-quarter 2026 revenue of $4.59 million coming in far below earlier models. Zymeworks has also disclosed it will not hold a conference call for this quarter, which limits management's ability to clarify results in real time. Key risk factors include the timing and recognition of milestone payments, potential pipeline setbacks, and the possibility that consensus estimates sit above the company's own guidance range.
Key Items to Monitor After the Release
Beyond the headline third-quarter number, investors should focus on whether management reaffirms or adjusts its full-year 2026 revenue and adjusted EBITDA guidance. A print near the top of consensus would suggest the anticipated milestone payments arrived on schedule, while a shortfall could signal delays or revised terms with collaboration partners.
Pipeline execution will remain a central theme. Zymeworks continues to advance assets such as zanidatamab and its pan-RAS ADC platform, and regulatory or clinical updates could shape the stock's trajectory more than quarterly financials alone. Investors should also watch cash management and any commentary on how long existing resources are expected to fund operations.
Finally, the sustainability of milestone-driven revenue is an open question. A single large quarter does not establish a recurring earnings base, so attention will turn to whether future milestones and royalties can fill the gap in coming periods. The stock's reaction may ultimately hinge less on the size of this quarter's windfall and more on the forward signals embedded in management's disclosures.
Using Tickeron’s AI Tools in My Research
When preparing for reports like this one, I often turn to Tickeron’s AI Screener to quickly scan the biotech sector for comparable setups and technical signals. It lets me filter by fundamentals, volatility, and AI-driven patterns in a single workflow, which helps put event-driven names in better context without spending hours on manual work. The tool has become a regular part of how I cross-check analyst models ahead of earnings.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ZYME in upward trend: price rose above 50-day moving average on October 20, 2026
ZYME moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend. In 37 of 40 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on ZYME as a result. In 66 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for ZYME just turned positive on October 20, 2026. Looking at past instances where ZYME's MACD turned positive, the stock continued to rise in 37 of 48 cases over the following month. The odds of a continued upward trend are 77%.
The 10-day moving average for ZYME crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 78%.
Following a +6.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where ZYME advanced for three days, in 252 of 296 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The 10-day RSI Indicator for ZYME moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 53 similar instances where the indicator moved out of overbought territory. In 41 of the 53 cases, the stock moved lower in the following days. This puts the odds of a move lower at 77%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZYME declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
ZYME broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ZYME entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. ZYME’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 74 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (25.653) is normal, around the industry mean (2.788). P/E Ratio (-14.225) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.911) among similar stocks. P/S Ratio (52.910) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 85 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZYME’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company for cancer & autoimmune treatment
Industry Biotechnology
Advertisement